Onsite Conferences and Activities 2019
Link Multiple Themes and Present Comprehensive Contents
Onsite Conferences 2018 Review
2018 Award for Top 100 Internationalized Companies
Excellent Suppliers and Partners in International Market (Top 60), Leading Formulation Suppliers (Top 20), and Promising Enterprises (Top 20) were selected on the basis of product export, international registration, overseas M&A, and international cooperation, etc. The lists were released before the show, and published to all exhibitors and visitors on the site of the show.
The 9th China-World CEO Summit
Themed by how to guarantee the balance and stability of API supply chain, the summit invited leaders of representative enterprises in the industry to a round table discussion to share successful experience and advices on addressing the above challenges, which provided references to resolve the current development predicament of the enterprises.
The 2nd CPhI Women in Leadership Forum
The forum was successfully held at Le Sun Chine one night before the show, to unveil the China Pharma Week. Themed by “new era, new women, new health”, the forum gathered over 60 women leaders of the pharma industry to share life insights and talk about experience in the workplace.
CPhI Networking Dinner
The CPhI Networking Dinner at the Bund took place as scheduled on the evening of June 20, with nearly 200 government officials, Chinese and overseas VIP buyers and pharmaceutical company executives attending the event, who shared insights with industry peers from all over the world, broadened the socializing resources, and obtained high-end connections in the industry while enjoying the night view of Huangpu River and tasting the dinner delicacies.
The Plant Visit continued the splendidness of the show after its close on 22 June. The organiser orchestrated 3 routes: Cutting-edge System & Engineering, Scientific & Innovative Instruments, and Amino Acid Manufacturing, leading nearly 40 professional visitors to the plant, which facilitated potential partners to get in touch with the culture and technology of suppliers closely, and feel the strength of ‘Made in China’.
CHP-JP Joint Forum
The 1st CHP-JP Joint Forum was successfully held in Shanghai on June 21 by Chinese Pharmacopoeia Commission and Society of Japanese Pharmacopoeia, with over 200 representatives from the China National Drug Administration, Ministry of Health, Labour and Welfare of Japan, Pharmaceuticals and Medical Devices Agency of Japan, Chinese Pharmacopoeia Commission, National Institutes for Food and Drug Control of China, and Chinese and Japanese institutions for pharmaceutical product research, production, and control present.
International Agencies Updates and Q&A
Experts from China National Drug Administration, Chinese Pharmacopoeia Commission, Center for Food and Drug Inspection of CFDA, Shanghai Municipal Food and Drug Administration, Delegation of the European Union to China, World Health Organization, U.S. Food and Drug Administration, European Directorate for the Quality of Medicines & HealthCare, United States Pharmacopeia Convention, British Standards Institute and Saudi Food and Drug Authority, etc. together with over 200 representatives from nearly 100 enterprises were present at the conference. The conference has been held for consecutive years, inviting Chinese and overseas pharmacopoeia and drug regulation agencies to share the recent dynamics of drug regulatory policies, laws and regulations and help enterprises improve levels in product registration application and quality system construction, which is not only a high-end, open, and sharing platform for Chinese and overseas pharmaceutical industries to exchange on drug regulatory laws and regulations, but also an important window for Chinese pharmaceutical industry to be synonymous with international standards.
2018 China-World Innovation and Development Forum
The speeches of the forum were focused on the policy and market which covered the pharmaceutical industry development situation and policy trends, CFDA’s latest reforms and influences thereof, analysis of the import & export and internationalisation situation of Chinese pharmaceutical products, pharmaceutical product patent protection, and market access and regulation, etc., to provide a high-level exchange platform for Chinese and overseas pharmaceutical entrepreneurs, industry experts, and relevant government departments, and offer keen insights and thorough analysis of the new environments and new situations of development of the Chinese and overseas pharmaceutical industries from the perspective of globalisation strategy.
P-MEC China Summit 2018
The P-MEC China Summit 2018 lasted for three days (June 20-22) and came to a successful conclusion, where lively and detailed speeches were given mainly focusing on topics like “Rationality of Deviation Investigation and Effective Management of CAPA”, “Technology Transfer Requirements in MAH”, and “Lean Manufacturing of Pharmaceuticals: How to create real competitiveness through effective integration with QA/QC”, with an audience of nearly 200 people and fantastic interactions during the discussion to let wisdom sparkle in the clash of ideas; it provided insiders with an excellent platform for analysing policies and regulations, discussing quality culture development, qualification and validation, and data integrity, and showcasing the latest technologies.
China Pharma Environmental Forum
The forum gathered an advisory group in the environmental policy field of China and an expert panel on environmental equipment and technology, to discuss the application of the environmental protection technology in the pharmaceutical industry under the New Normal, and bring interpretations of the latest pharmaceutical environmental protection policies and green and environmental protection application solutions.
5th China BioPh Outlook Summit
Kicked off on June 21, the 5th China BioPh Outlook Summit, an important conference of the biopharmaceutical industry, invited over 20 Chinese and oversea senior pharmaceutical experts to form a luxury speaker lineup, from well-known pharmaceutical enterprises like Amgen, Bayer, Roche, Henlius, WuXi AppTec, and Simcere, and professional agencies like Shanghai Biopharmaceutics Industry Association, Shanghai Drug Evaluation and Inspection Center, SAPA, and RDPAC, to focus on analysis of Chinese and overseas biological drug markets and policies, explore the R&D trends of innovative biological drugs, discuss the new R&D trends of anti-cancer drugs, and share about the new developments of tumor immunotherapy and other hot topics. Over 300 industry elites were present on site, to “feel the pulse” for the future of China’s biopharmaceuticals.
2018 Drug Safety and Quality Management Forum
On June 20, experts from the government, drug regulators, Chinese and overseas enterprises, and research institutes conducted heated discussions and exchanges by centering on China’s quality management system under the new situation, tracking of the latest regulatory policies for pharmaceutical product safety, exploration of drug safety detection and risk control, and application of new biological technologies, etc. This forum enabled attendees to see the development trends and bright prospects of China’s bio-medicine industry, and that the drug R&D will raise higher requirements for China’s laboratory instrument industry.
International Business Programme
Featuring two tracks, the International Business Programme was developed with both domestic and international visitors in mind, with sessions to address the key trends, topics and developments for international partners looking to expand to or within the Chinese market and domestic partners looking to grow operations outside of China or draw learnings from international partners.